RESUMEN
Myoclonus-dystonia (M-D) is a movement disorder that is often associated with mutations in epsilon-sarcoglycan (SGCE), a maternally imprinted gene at 7q21.3. We report a 24-year-old male with short stature (<5th percentile) and a movement disorder clinically consistent with M-D. Single nucleotide polymorphism (SNP) array did not identify significant copy number changes, but revealed three long continuous stretches of homozygosity on chromosome 7 suggestive of uniparental disomy. Parental SNP arrays confirmed that the proband had maternal uniparental disomy of chromosome 7 (mUPD7) with regions of heterodisomy and isodisomy. mUPD7 is the cause of approximately 5-10% of Silver-Russell syndrome (SRS), a disorder characterized by prenatal and postnatal growth retardation. Although SRS was not suspected in our patient, these findings explain his short stature. SGCE methylation testing showed loss of the unmethylated paternal allele. Our findings provide a unifying diagnosis for his short stature and M-D and help to optimize his medication regimen. In conclusion, we show that M-D is a clinical feature that may be associated with SRS due to mUPD7. Individuals with mUPD7 should be monitored for the development of movement disorders. Conversely, individuals with M-D and short stature should be evaluated for SRS.
Asunto(s)
Cromosomas Humanos Par 7 , Trastornos Distónicos/genética , Síndrome de Silver-Russell/genética , Disomía Uniparental , Alelos , Islas de CpG , Metilación de ADN , Humanos , Pérdida de Heterocigocidad , Masculino , Fenotipo , Polimorfismo de Nucleótido Simple , Regiones Promotoras Genéticas , Sarcoglicanos/genética , Adulto JovenRESUMEN
Parkinson disease (PD) is a neurodegenerative disease characterized by tremor, bradykinesia, rigidity and postural instability. Post-mortem examination shows loss of neurons and Lewy bodies, which are cytoplasmic eosinophilic inclusions, in the substantia nigra and other brain regions. A few families have PD caused by mutations (A53T or A30P) in the gene SNCA (encoding alpha-synuclein). Alpha-synuclein is present in Lewy bodies of patients with sporadic PD, suggesting that alpha-synuclein may be involved in the pathogenesis of PD. It is unknown how alpha-synuclein contributes to the cellular and biochemical mechanisms of PD, and its normal functions and biochemical properties are poorly understood. To determine the protein-interaction partners of alpha-synuclein, we performed a yeast two-hybrid screen. We identified a novel interacting protein, which we term synphilin-1 (encoded by the gene SNCAIP). We found that alpha-synuclein interacts in vivo with synphilin-1 in neurons. Co-transfection of both proteins (but not control proteins) in HEK 293 cells yields cytoplasmic eosinophilic inclusions.
Asunto(s)
Proteínas Portadoras/metabolismo , Cuerpos de Inclusión/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Secuencia de Aminoácidos , Animales , Química Encefálica , Proteínas Portadoras/genética , Línea Celular , Cromosomas Humanos Par 5/genética , Femenino , Humanos , Cuerpos de Lewy/metabolismo , Masculino , Datos de Secuencia Molecular , Proteínas del Tejido Nervioso/genética , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/metabolismo , Plásmidos/genética , Unión Proteica , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Saccharomyces cerevisiae/genética , Homología de Secuencia de Aminoácido , Sinucleínas , Distribución Tisular , Extractos de Tejidos/metabolismo , Transfección , alfa-SinucleínaRESUMEN
We show that the nonimmunosuppressive analogues of the immunosuppressive drugs FK506, rapamycin and cyclosporin A promote neurite outgrowth both in PC12 cells and sensory neuronal cultures of dorsal root ganglia with potencies resembling their immunosuppressive homologues. Neurotrophic potencies of the immunophilin ligands resemble their potencies in binding to and inhibiting the rotamase activity of FKBP-12 of cyclophilin. Since nonimmunosuppressive immunophilin ligands, which are devoid of calcineurin inhibitory activity, are equally neurotrophic, inhibition of calcineurin activity is not the mediator of the neurotrophic effects. The immunophilin ligands are neurotrophic in intact animals. FK506 and L-685,818 (the C18-hydroxy, C21-ethyl derivative of FK506) treatment of rats with crushed sciatic nerves enhances both functional and morphologic recovery. The striking potency of these agents, their bioavailability and the dissociation of neurotrophic from immunosuppressant actions argue for their therapeutic relevance in the treatment of neurodegenerative diseases.
Asunto(s)
Ciclosporinas/farmacología , Inmunosupresores/farmacología , Neuronas/efectos de los fármacos , Piperidinas/farmacología , Piridazinas/farmacología , Tacrolimus/análogos & derivados , Animales , Células Cultivadas , Embrión de Pollo , Ciclosporina/farmacología , Ganglios Espinales/citología , Regeneración Nerviosa/efectos de los fármacos , Neuritas/efectos de los fármacos , Neuronas Aferentes/citología , Células PC12 , Polienos/farmacología , Ratas , Nervio Ciático/efectos de los fármacos , Sirolimus , Tacrolimus/farmacologíaRESUMEN
Nitric oxide (NO) and peroxynitrite, formed from NO and superoxide anion, have been implicated as mediators of neuronal damage following focal ischemia, but their molecular targets have not been defined. One candidate pathway is DNA damage leading to activation of the nuclear enzyme, poly(ADP-ribose) polymerase (PARP), which catalyzes attachment of ADP ribose units from NAD to nuclear proteins following DNA damage. Excessive activation of PARP can deplete NAD and ATP, which is consumed in regeneration of NAD, leading to cell death by energy depletion. We show that genetic disruption of PARP provides profound protection against glutamate-NO-mediated ischemic insults in vitro and major decreases in infarct volume after reversible middle cerebral artery occlusion. These results provide compelling evidence for a primary involvement of PARP activation in neuronal damage following focal ischemia and suggest that therapies designed towards inhibiting PARP may provide benefit in the treatment of cerebrovascular disease.
Asunto(s)
Benzamidas/farmacología , Encéfalo/fisiopatología , Ataque Isquémico Transitorio/prevención & control , Isoquinolinas/farmacología , Neuronas/fisiología , Piperidinas/farmacología , Poli(ADP-Ribosa) Polimerasas/deficiencia , Poli(ADP-Ribosa) Polimerasas/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Encéfalo/patología , Encéfalo/fisiología , Células Cultivadas , Corteza Cerebral/citología , Circulación Cerebrovascular , Daño del ADN , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Hemodinámica , Inmunidad Innata , Ataque Isquémico Transitorio/patología , Ratones , Ratones Noqueados , N-Metilaspartato/toxicidad , NAD/metabolismo , Neuronas/efectos de los fármacos , Neuronas/patología , Neurotoxinas/toxicidad , Nitratos/fisiología , Óxido Nítrico/fisiología , Poli(ADP-Ribosa) Polimerasas/genéticaRESUMEN
Idiopathic voiding disorders affect up to 10-15% of men and women. We describe bladder abnormalities in mice with targeted deletion of the gene for neuronal nitric oxide synthase which model the clinical disorders. The mice possess hypertrophic dilated bladders and dysfunctional urinary outlets which do not relax in response to electrical field stimulation or L-arginine. The mice also display increased urinary frequency.
Asunto(s)
Modelos Animales de Enfermedad , Óxido Nítrico Sintasa/fisiología , Uretra/fisiopatología , Vejiga Urinaria/fisiopatología , Trastornos Urinarios/fisiopatología , Animales , Arginina/farmacología , Estimulación Eléctrica , Endotelio Vascular/química , Humanos , Hipertrofia , Masculino , Ratones , Ratones Endogámicos C57BL , Contracción Muscular/efectos de los fármacos , Neuronas/enzimología , Óxido Nítrico/fisiología , Óxido Nítrico Sintasa/análisis , Óxido Nítrico Sintasa/genética , Nitroprusiato/farmacología , Uretra/química , Vejiga Urinaria/química , Vejiga Urinaria/inervación , Urotelio/químicaRESUMEN
Parkinson disease is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons and the presence of intracytoplasmic-ubiquitinated inclusions (Lewy bodies). Mutations in alpha-synuclein (A53T, A30P) and parkin cause familial Parkinson disease. Both these proteins are found in Lewy bodies. The absence of Lewy bodies in patients with parkin mutations suggests that parkin might be required for the formation of Lewy bodies. Here we show that parkin interacts with and ubiquitinates the alpha-synuclein-interacting protein, synphilin-1. Co-expression of alpha-synuclein, synphilin-1 and parkin result in the formation of Lewy-body-like ubiquitin-positive cytosolic inclusions. We further show that familial-linked mutations in parkin disrupt the ubiquitination of synphilin-1 and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy-body-associated proteins and link parkin and alpha-synuclein in a common pathogenic mechanism through their interaction with synphilin-1.
Asunto(s)
Proteínas Portadoras/metabolismo , Ligasas/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Enfermedad de Parkinson/metabolismo , Ubiquitina-Proteína Ligasas , Animales , Línea Celular , Glicosilación , Humanos , Cuerpos de Lewy , Ligasas/genética , Mutagénesis , Proteínas del Tejido Nervioso/genética , Ratas , Sinucleínas , Ubiquitinas/metabolismo , alfa-SinucleínaRESUMEN
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) damages dopaminergic neurons as seen in Parkinson disease. Here we show that after administration of MPTP to mice, there was a robust gliosis in the substantia nigra pars compacta associated with significant upregulation of inducible nitric oxide synthase (iNOS). These changes preceded or paralleled MPTP-induced dopaminergic neurodegeneration. We also show that mutant mice lacking the iNOS gene were significantly more resistant to MPTP than their wild-type littermates. This study demonstrates that iNOS is important in the MPTP neurotoxic process and indicates that inhibitors of iNOS may provide protective benefit in the treatment of Parkinson disease.
Asunto(s)
Intoxicación por MPTP/enzimología , Intoxicación por MPTP/etiología , Degeneración Nerviosa/enzimología , Degeneración Nerviosa/etiología , Óxido Nítrico Sintasa/metabolismo , Enfermedad de Parkinson/enzimología , Enfermedad de Parkinson/etiología , Animales , Modelos Animales de Enfermedad , Dopamina/metabolismo , Inhibidores Enzimáticos/farmacología , Expresión Génica/efectos de los fármacos , Intoxicación por MPTP/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Microglía/efectos de los fármacos , Microglía/enzimología , Degeneración Nerviosa/tratamiento farmacológico , Óxido Nítrico Sintasa/deficiencia , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa de Tipo II , Enfermedad de Parkinson/tratamiento farmacológico , ARN Mensajero/genética , ARN Mensajero/metabolismoRESUMEN
Poly(adenosine 5'-diphosphoribose) synthetase (PARS) is a nuclear enzyme which, when activated by DNA strand breaks, adds up to 100 adenosine 5'-diphosphoribose (ADP-ribose) units to nuclear proteins such as histones and PARS itself. This activation can lead to cell death through depletion of beta-nicotinamide adenine dinucleotide (the source of ADP-ribose) and adenosine triphosphate. Nitric oxide (NO) stimulated ADP-ribosylation of PARS in rat brain. Benzamide and other derivatives, which inhibit PARS, blocked N-methyl-D-aspartate- and NO-mediated neurotoxicity with relative potencies paralleling their ability to inhibit PARS. Thus, NO appeared to elicit neurotoxicity by activating PARS.
Asunto(s)
N-Metilaspartato/toxicidad , Neuronas/efectos de los fármacos , Óxido Nítrico/toxicidad , Poli(ADP-Ribosa) Polimerasas/metabolismo , Animales , Benzamidas/farmacología , Encéfalo/citología , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Muerte Celular/efectos de los fármacos , Línea Celular , Células Cultivadas , Corteza Cerebral/citología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/enzimología , Daño del ADN , Activación Enzimática , Humanos , Neuronas/citología , Neuronas/enzimología , Inhibidores de Poli(ADP-Ribosa) Polimerasas , Ratas , Ratas Sprague-DawleyRESUMEN
beta-Adrenergic receptor kinase (beta ARK) and beta-arrestin function in the homologous or agonist-activated desensitization of G protein-coupled receptors. The isoforms beta ARK-2 and beta-arrestin-2 are highly enriched in and localized to the dendritic knobs and cilia of the olfactory receptor neurons where the initial events of olfactory signal transduction occur. Odorants induce a rapid and transient elevation of adenosine 3',5'-monophosphate (cAMP), which activates a nonspecific cation channel and produces membrane depolarization. Preincubation of rat olfactory cilia with antibodies raised against beta ARK-2 and beta-arrestin-2 increased the odorant-induced elevation of cAMP and attenuated desensitization. These results suggest that beta ARK-2 and beta-arrestin-2 mediate agonist-dependent desensitization in olfaction.
Asunto(s)
Antígenos/metabolismo , Arrestinas , Proteínas Quinasas Dependientes de AMP Cíclico , Proteínas del Ojo/metabolismo , Proteínas de Unión al GTP/metabolismo , Mecanorreceptores/fisiología , Neuronas/fisiología , Odorantes , Bulbo Olfatorio/fisiología , Proteínas Quinasas/metabolismo , Receptores Adrenérgicos beta/fisiología , Olfato , Cornetes Nasales/fisiología , Animales , Células Cultivadas , AMP Cíclico/metabolismo , Citosol/metabolismo , Dendritas/fisiología , Quinasa 2 del Receptor Acoplado a Proteína-G , Isoenzimas/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Testículo/fisiología , Quinasas de Receptores Adrenérgicos beta , Arrestina beta 2 , beta-ArrestinasRESUMEN
Expanded polyglutamine repeats have been proposed to cause neuronal degeneration in Huntington's disease (HD) and related disorders, through abnormal interactions with other proteins containing short polyglutamine tracts such as the transcriptional coactivator CREB binding protein, CBP. We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain. Expanded polyglutamine repeats specifically interfere with CBP-activated gene transcription, and overexpression of CBP rescued polyglutamine-induced neuronal toxicity. Thus, polyglutamine-mediated interference with CBP-regulated gene transcription may constitute a genetic gain of function, underlying the pathogenesis of polyglutamine disorders.
Asunto(s)
Enfermedad de Huntington/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Neuronas/metabolismo , Proteínas Nucleares/metabolismo , Péptidos/metabolismo , Transactivadores/metabolismo , Transcripción Genética , Animales , Encéfalo/metabolismo , Proteína de Unión a CREB , Núcleo Celular/metabolismo , Supervivencia Celular , Células Cultivadas , Humanos , Proteína Huntingtina , Enfermedad de Huntington/genética , Ratones , Ratones Transgénicos , Mutación , Proteínas del Tejido Nervioso/química , Proteínas del Tejido Nervioso/genética , Neuronas/citología , Proteínas Nucleares/química , Proteínas Nucleares/genética , Péptidos/química , Secuencias Repetitivas de Aminoácido , Transactivadores/química , Transfección , Células Tumorales CultivadasRESUMEN
Long-term potentiation (LTP) is a persistent increase in synaptic strength implicated in certain forms of learning and memory. In the CA1 region of the hippocampus, LTP is thought to involve the release of one or more retrograde messengers from the postsynaptic cell that act on the presynaptic terminal to enhance transmitter release. One candidate retrograde messenger is the membrane-permeant gas nitric oxide (NO), which in the brain is released after activation of the neuronal-specific NO synthase isoform (nNOS). To assess the importance of NO in hippocampal synaptic plasticity, LTP was examined in mice where the gene encoding nNOS was disrupted by gene targeting. In nNOS- mice, LTP induced by weak intensity tetanic stimulation was normal except for a slight reduction in comparison to that in wild-type mice and was blocked by NOS inhibitors, just as it was in wild-type mice. Immunocytochemical studies indicate that in the nNOS- mice as in wild-type mice, the endothelial form of NOS (eNOS) is expressed in CA1 neurons. These findings suggest that eNOS, rather than nNOS, generates NO within the postsynaptic cell during LTP.
Asunto(s)
Aminoácido Oxidorreductasas/metabolismo , Arginina/análogos & derivados , Hipocampo/fisiología , Potenciación a Largo Plazo , Óxido Nítrico/metabolismo , Células Piramidales/fisiología , Aminoácido Oxidorreductasas/antagonistas & inhibidores , Aminoácido Oxidorreductasas/genética , Animales , Arginina/farmacología , Estimulación Eléctrica , Endotelio/enzimología , Hipocampo/efectos de los fármacos , Hipocampo/enzimología , Técnicas In Vitro , Potenciación a Largo Plazo/efectos de los fármacos , Ratones , Mutación , Óxido Nítrico Sintasa , Nitroarginina , Células Piramidales/efectos de los fármacos , Células Piramidales/enzimología , Transmisión Sináptica/efectos de los fármacosRESUMEN
Indirect mechanisms are implicated in the pathogenesis of the dementia associated with human immunodeficiency virus-type 1 (HIV-1) infection. Proinflammatory molecules such as tumor necrosis factor alpha and eicosanoids are elevated in the central nervous system of patients with HIV-1-related dementia. Nitric oxide (NO) is a potential mediator of neuronal injury, because cytokines may activate the immunologic (type II) isoform of NO synthase (iNOS). The levels of iNOS in severe HIV-1-associated dementia coincided with increased expression of the HIV-1 coat protein gp41. Furthermore, gp41 induced iNOS in primary cultures of mixed rat neuronal and glial cells and killed neurons through a NO-dependent mechanism. Thus, gp41-induced NO formation may contribute to the severe cognitive dysfunction associated with HIV-1 infection.
Asunto(s)
Complejo SIDA Demencia/enzimología , Encéfalo/enzimología , Proteína gp41 de Envoltorio del VIH/metabolismo , VIH-1 , Óxido Nítrico Sintasa/biosíntesis , Complejo SIDA Demencia/metabolismo , Animales , Encéfalo/metabolismo , Muerte Celular , Células Cultivadas , Corteza Cerebral/enzimología , Corteza Cerebral/metabolismo , Inducción Enzimática , Proteína gp120 de Envoltorio del VIH/metabolismo , Proteína gp120 de Envoltorio del VIH/farmacología , Proteína gp41 de Envoltorio del VIH/farmacología , Humanos , Neuroglía/citología , Neuronas/citología , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa/genética , Reacción en Cadena de la Polimerasa , RatasRESUMEN
Nitric oxide (NO) is a diffusible free radical that functions as a second messenger and neurotransmitter. NO synthase (NOS) is highly and transiently expressed in neurons of the developing olfactory epithelium during migration and establishment of primary synapses in the olfactory bulb. NOS is first expressed at E11 in cells of the presumptive nervous layer of the olfactory placode. NOS immunoreactivity persists in the descendants of these cells that differentiate into embryonic olfactory receptor neurons (ORNs). Olfactory NOS expression in the ORN and in its afferents rapidly declines after birth and is undetectable by P7. Following bulbectomy, NOS expression is rapidly induced in the regenerating ORN and is particularly enriched in their outgrowing axons. Immunoblot and Northern blot analyses similarly demonstrate an induction of NOS protein and mRNA expression, respectively, the highest levels of which coincide with peaks of ORN regeneration. These data argue against a role for NO in odorant-sensitive signal transduction, but suggest a prominent function for NO in activity-dependent establishment of connections in both developing and regenerating olfactory neurons.
Asunto(s)
Aminoácido Oxidorreductasas/metabolismo , Óxido Nítrico/farmacología , Mucosa Olfatoria/embriología , Neuronas Receptoras Olfatorias/enzimología , Receptores Odorantes/fisiología , Animales , Expresión Génica , Inmunohistoquímica , Proteínas del Tejido Nervioso/metabolismo , Óxido Nítrico Sintasa , Proteína Marcadora Olfativa , ARN Mensajero/genética , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Transmisión SinápticaRESUMEN
Nitric oxide is a free radical that has been recently recognized as a neural messenger molecule. Nitric oxide synthase has now been purified and molecularly cloned from brain. Using specific antibodies and oligonucleotide probes, we have localized brain nitric oxide synthase to discrete neuronal populations in the rat and primate brain. Nitric oxide synthase is exclusively neuronal, and its localization is absolutely coincident with NADPH diaphorase staining in both rat and primate.
Asunto(s)
Aminoácido Oxidorreductasas/metabolismo , Encéfalo/metabolismo , NADPH Deshidrogenasa/metabolismo , Neuronas/metabolismo , ARN Mensajero/metabolismo , Aminoácido Oxidorreductasas/genética , Animales , Western Blotting , Haplorrinos , Inmunohistoquímica , Masculino , Óxido Nítrico Sintasa , Hibridación de Ácido Nucleico , Pruebas de Precipitina , Ratas , Ratas Endogámicas , Coloración y Etiquetado , Distribución TisularRESUMEN
The mitochondrial protein, endonuclease G (EndoG), is one of the endonucleases implicated in DNA fragmentation during apoptosis. It has been shown to translocate from the mitochondria to the nucleus upon cell death stimuli. These observations suggest that EndoG is a mitochondrial cell death effector, and that it possibly acts as a cell death nuclease, similar to DNA fragmentation factor. To better understand the role of EndoG in development and apoptosis, we generated EndoG null mice by homologous gene targeting without disruption of D2Wsu81e. EndoG null mice are viable and develop to adulthood with no obvious abnormalities. Fibroblasts generated from the EndoG null mice show no difference in susceptibility when induced to die by a variety of intrinsic and extrinsic apoptotic stimuli. Additionally, EndoG null mice are equally sensitive to excitotoxic stress. These data suggest that EndoG is not essential for early embryogenesis and apoptosis.
Asunto(s)
Apoptosis/fisiología , Desarrollo Embrionario/fisiología , Endodesoxirribonucleasas/metabolismo , Animales , Apoptosis/efectos de los fármacos , Factor Inductor de la Apoptosis/metabolismo , Encéfalo/embriología , Encéfalo/enzimología , Encéfalo/crecimiento & desarrollo , Núcleo Celular/metabolismo , Células Cultivadas , Relación Dosis-Respuesta a Droga , Desarrollo Embrionario/genética , Endodesoxirribonucleasas/genética , Etopósido/farmacología , Femenino , Fibroblastos/citología , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Inmunohistoquímica , Metilnitronitrosoguanidina/farmacología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Ratones Noqueados , Mitocondrias/enzimología , Embarazo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
BACKGROUND: Nitric oxide is a messenger molecule of the nervous system, which is produced by the enzyme nitric oxide synthase, which may regulate cyclic guanosine monophosphate levels and which has been implicated in the control of neurotransmitter release. PC-12 pheochromocytoma cells differentiate to form neuronal cells in culture when they are exposed to nerve growth factor. The levels of cyclic guanosine monophosphate in the cells and their ability to release acetylcholine in response to K(+)-depolarization are both maximal after eight days of treatment with nerve growth factor. We set out to assess a possible role for nitric oxide in the processes that occur in differentiating PC-12 cells. RESULTS: Nitric oxide synthase is first evident in differentiating PC-12 cells eight days after beginning treatment with nerve growth factor, coinciding with the marked increase in K(+)-depolarization-induced release of acetylcholine. The release of both acetylcholine and dopamine in response to K(+)-depolarization is blocked by inhibitors of nitric oxide synthase and by hemoglobin, which binds nitric oxide. Providing l-arginine, a precursor required for nitric oxide synthesis, reverses the effects of the inhibitors. In synaptosomal preparations from the corpus striatum, inhibitors of nitric oxide synthase prevent the release of glutamate in response to the glutamate derivative N-methyl-d-aspartate but not in response to K(+)-depolarization. CONCLUSION: Nitric oxide may mediate the release of acetylcholine and dopamine in response to K(+)-depolarization in PC-12 cells and the release of glutamate in response to N-methyl-d-aspartate in striatal synaptosomes. Nitric oxide synthase expression is induced after eight days of treating PC-12 cells with nerve growth factor, coinciding with a marked enhancement of the release of neurotransmitters in response to K(+)-depolarization.
RESUMEN
Nitric oxide (NO) synthesized within mammalian sinoatrial cells has been shown to participate in cholinergic control of heart rate (HR). However, it is not known whether NO synthesized within neurons plays a role in HR regulation. HR dynamics were measured in 24 wild-type (WT) mice and 24 mice in which the gene for neuronal NO synthase (nNOS) was absent (nNOS-/- mice). Mean HR and HR variability were compared in subsets of these animals at baseline, after parasympathetic blockade with atropine (0.5 mg/kg i.p.), after beta-adrenergic blockade with propranolol (1 mg/kg i.p.), and after combined autonomic blockade. Other animals underwent pressor challenge with phenylephrine (3 mg/kg i.p.) after beta-adrenergic blockade to test for a baroreflex-mediated cardioinhibitory response. The latter experiments were then repeated after inactivation of inhibitory G proteins with pertussis toxin (PTX) (30 microgram/kg i.p.). At baseline, nNOS-/- mice had higher mean HR (711+/-8 vs. 650+/-8 bpm, P = 0.0004) and lower HR variance (424+/-70 vs. 1,112+/-174 bpm2, P = 0.001) compared with WT mice. In nNOS-/- mice, atropine administration led to a much smaller change in mean HR (-2+/-9 vs. 49+/-5 bpm, P = 0.0008) and in HR variance (64+/-24 vs. -903+/-295 bpm2, P = 0.02) than in WT mice. In contrast, propranolol administration and combined autonomic blockade led to similar changes in mean HR between the two groups. After beta-adrenergic blockade, phenylephrine injection elicited a fall in mean HR and rise in HR variance in WT mice that was partially attenuated after treatment with PTX. The response to pressor challenge in nNOS-/- mice before PTX administration was similar to that in WT mice. However, PTX-treated nNOS-/- mice had a dramatically attenuated response to phenylephrine. These findings suggest that the absence of nNOS activity leads to reduced baseline parasympathetic tone, but does not prevent baroreflex-mediated cardioinhibition unless inhibitory G proteins are also inactivated. Thus, neuronally derived NO and cardiac inhibitory G protein activity serve as parallel pathways to mediate autonomic slowing of heart rate in the mouse.
Asunto(s)
Presión Sanguínea/fisiología , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/metabolismo , Frecuencia Cardíaca/fisiología , Óxido Nítrico Sintasa/metabolismo , Animales , Atropina/farmacología , Sistema Nervioso Autónomo/efectos de los fármacos , Sistema Nervioso Autónomo/fisiología , Barorreflejo/efectos de los fármacos , Barorreflejo/fisiología , Presión Sanguínea/efectos de los fármacos , Electrocardiografía/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Homeostasis , Ratones , Ratones Noqueados , Modelos Cardiovasculares , Óxido Nítrico Sintasa/deficiencia , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa de Tipo II , Fenilefrina/farmacología , Propranolol/farmacología , Transducción de Señal/fisiologíaRESUMEN
Translocation of apoptosis-inducing factor (AIF) from the mitochondria to the nucleus can play a major role in neuronal death elicited by oxidant stress. The time course of nuclear translocation of AIF after experimental stroke may vary with the severity of injury and may be accelerated by oxidant stress associated with reperfusion and nitric oxide (NO) production. Western immunoblots of AIF on nuclear fractions of ischemic hemisphere of male mice showed no significant increase with 1 h of middle cerebral artery occlusion and no reperfusion, whereas increases were detectable after 6 and 24 h of permanent ischemia. However, as little as 20 min of reperfusion after 1 h of middle cerebral artery occlusion resulted in an increase in nuclear AIF coincident with an increase in poly(ADP-ribose) polymer (PAR) formation. Further nuclear AIF accumulation was seen at 6 and 24 h of reperfusion. In contrast, 20 min of reperfusion after 2 h of occlusion did not increase nuclear AIF. In this case, nuclear AIF became detectable at 6 and 24 h of reperfusion. With brief occlusion of 30 min duration, nuclear AIF remained undetectable at both 20 min and 6 h and became evident only after 24 h of reperfusion. Inhibition of neuronal NO synthase attenuated formation of PAR and nuclear AIF accumulation. Gene deletion of neuronal NO synthase also attenuated nuclear AIF accumulation. Therefore, reperfusion accelerates AIF translocation to the nucleus when focal ischemia is of moderate duration (1 h), but is markedly delayed after brief ischemia (30 min). Nuclear translocation of AIF eventually occurs with prolonged focal ischemia with or without reperfusion. Neuronally-derived NO is a major factor contributing to nuclear AIF accumulation after stroke.
Asunto(s)
Factor Inductor de la Apoptosis/metabolismo , Núcleo Celular/metabolismo , Ataque Isquémico Transitorio/patología , Neuronas/enzimología , Óxido Nítrico Sintasa de Tipo I/metabolismo , Animales , Conducta Animal/fisiología , Western Blotting , Inhibidores Enzimáticos/farmacología , Eliminación de Gen , Indazoles/farmacología , Infarto de la Arteria Cerebral Media/patología , Infarto de la Arteria Cerebral Media/psicología , Ataque Isquémico Transitorio/psicología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo I/genética , Poli Adenosina Difosfato Ribosa/metabolismo , Transporte de Proteínas , Daño por Reperfusión/patología , Daño por Reperfusión/psicología , Fracciones Subcelulares/metabolismo , Factores de TiempoRESUMEN
Poly(ADP-ribose) polymerases (PARPs) are members of a family of enzymes that utilize nicotinamide adenine dinucleotide (NAD(+)) as substrate to form large ADP-ribose polymers (PAR) in the nucleus. PAR has a very short half-life due to its rapid degradation by poly(ADP-ribose) glycohydrolase (PARG). PARP-1 mediates acute neuronal cell death induced by a variety of insults including cerebral ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism, and CNS trauma. While PARP-1 is localized to the nucleus, PARG resides in both the nucleus and cytoplasm. Surprisingly, there appears to be only one gene encoding PARG activity, which has been characterized in vitro to generate different splice variants, in contrast to the growing family of PARPs. Little is known regarding the spatial and functional relationships of PARG and PARP-1. Here we evaluate PARG expression in the brain and its cellular and subcellular distribution in relation to PARP-1. Anti-PARG (alpha-PARG) antibodies raised in rabbits using a purified 30 kDa C-terminal fragment of murine PARG recognize a single band at 111 kDa in the brain. Western blot analysis also shows that PARG and PARP-1 are evenly distributed throughout the brain. Immunohistochemical studies using alpha-PARG antibodies reveal punctate cytosolic staining, whereas anti-PARP-1 (alpha-PARP-1) antibodies demonstrate nuclear staining. PARG is enriched in the mitochondrial fraction together with manganese superoxide dismutase (MnSOD) and cytochrome C (Cyt C) following whole brain subcellular fractionation and Western blot analysis. Confocal microscopy confirms the co-localization of PARG and Cyt C. Finally, PARG translocation to the nucleus is triggered by NMDA-induced PARP-1 activation. Therefore, the subcellular segregation of PARG in the mitochondria and PARP-1 in the nucleus suggests that PARG translocation is necessary for their functional interaction. This translocation is PARP-1 dependent, further demonstrating a functional interaction of PARP-1 and PARG in the brain.
Asunto(s)
Química Encefálica/fisiología , Encéfalo/enzimología , Núcleo Celular/enzimología , Glicósido Hidrolasas/metabolismo , Neuronas/enzimología , Poli(ADP-Ribosa) Polimerasas/metabolismo , Transporte Activo de Núcleo Celular/fisiología , Animales , Biomarcadores/análisis , Biomarcadores/metabolismo , Compartimento Celular/genética , Línea Celular , Núcleo Celular/ultraestructura , Células Cultivadas , Regulación Enzimológica de la Expresión Génica/fisiología , Glicósido Hidrolasas/genética , Humanos , Inmunohistoquímica , Ratones , Ratones Noqueados , Mitocondrias/enzimología , Mitocondrias/genética , Proteínas del Tejido Nervioso/análisis , Proteínas del Tejido Nervioso/metabolismo , Neuronas/ultraestructura , Poli(ADP-Ribosa) Polimerasa-1 , Poli(ADP-Ribosa) Polimerasas/genética , Transporte de Proteínas/fisiología , Ratas , Fracciones SubcelularesRESUMEN
A unifying feature of neurodegenerative diseases is the abnormal accumulation and processing of mutant or damaged intra- and extracellular proteins; this leads to selective neuronal vulnerability and dysfunction. The ubiquitin-proteasomal pathway (UPP) is poised to play a central role in the processing of damaged and toxic proteins by ubiquitin-dependent proteolysis. The UPP can be overwhelmed in several neurodegenerative diseases. This results in the accumulation of toxic proteins and the formation of inclusions, and ultimately to neuronal dysfunction and cell death. Further analysis of the cellular and molecular mechanisms by which the UPP influences the detoxification of damaged and toxic proteins in neurodegenerative diseases could provide novel concepts and targets for the treatment and understanding of the pathogenesis of these devastating disorders.